These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 33211212)

  • 61. Effect of teriparatide on bone mineral density and biochemical markers in Japanese women with postmenopausal osteoporosis: a 6-month dose-response study.
    Miyauchi A; Matsumoto T; Shigeta H; Tsujimoto M; Thiebaud D; Nakamura T
    J Bone Miner Metab; 2008; 26(6):624-34. PubMed ID: 18979163
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis.
    Farahmand P; Marin F; Hawkins F; Möricke R; Ringe JD; Glüer CC; Papaioannou N; Minisola S; Martínez G; Nolla JM; Niedhart C; Guañabens N; Nuti R; Martín-Mola E; Thomasius F; Peña J; Graeff C; Kapetanos G; Petto H; Gentzel A; Reisinger A; Zysset PK
    Osteoporos Int; 2013 Dec; 24(12):2971-81. PubMed ID: 23740422
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
    Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Four-Year Teriparatide Followed by Denosumab
    Hirooka Y; Nozaki Y; Okuda S; Sugiyama M; Kinoshita K; Funauchi M; Matsumura I
    Front Endocrinol (Lausanne); 2021; 12():753185. PubMed ID: 34646240
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Retreatment with teriparatide: our experience in three patients with severe secondary osteoporosis.
    Mana DL; Zanchetta MB; Zanchetta JR
    Osteoporos Int; 2017 Apr; 28(4):1491-1494. PubMed ID: 27966106
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis.
    Keaveny TM; Donley DW; Hoffmann PF; Mitlak BH; Glass EV; San Martin JA
    J Bone Miner Res; 2007 Jan; 22(1):149-57. PubMed ID: 17042738
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis.
    Rizzoli R; Greenspan SL; Bone G; Schnitzer TJ; Watts NB; Adami S; Foldes AJ; Roux C; Levine MA; Uebelhart B; Santora AC; Kaur A; Peverly CA; Orloff JJ;
    J Bone Miner Res; 2002 Nov; 17(11):1988-96. PubMed ID: 12412806
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis.
    Chen P; Miller PD; Delmas PD; Misurski DA; Krege JH
    J Bone Miner Res; 2006 Nov; 21(11):1785-90. PubMed ID: 17002571
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The efficiency and safety of alendronate versus teriparatide for treatment glucocorticoid-induced osteoporosis: A meta-analysis and systematic review of randomized controlled trials.
    Liu ZM; Zhang M; Zong Y; Zhang D; Shen ZB; Guan XQ; Yin F
    PLoS One; 2022; 17(5):e0267706. PubMed ID: 35639783
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.
    Lems WF; Lodder MC; Lips P; Bijlsma JW; Geusens P; Schrameijer N; van de Ven CM; Dijkmans BA
    Osteoporos Int; 2006; 17(5):716-23. PubMed ID: 16463007
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Once-weekly teriparatide treatment on osteoporosis].
    Nakano T
    Clin Calcium; 2014 Jan; 24(1):100-5. PubMed ID: 24369286
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Comparative analysis of anti-osteoporosis medications in preventing vertebral body fractures after balloon kyphoplasty.
    Ueno M; Tajima Y; Ito S; Tsuji M; Toriumi E; Yoshii A; Otake N; Tanaka H
    Arch Osteoporos; 2024 Mar; 19(1):19. PubMed ID: 38512565
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Improvement in Glucocorticoid-Induced Osteoporosis on Switching from Bisphosphonates to Once-Weekly Teriparatide: A Randomized Open-Label Trial.
    Nanki T; Kawazoe M; Uno K; Hirose W; Dobashi H; Kataoka H; Mimura T; Hagino H; Kono H
    J Clin Med; 2022 Dec; 12(1):. PubMed ID: 36615091
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters.
    Arlot M; Meunier PJ; Boivin G; Haddock L; Tamayo J; Correa-Rotter R; Jasqui S; Donley DW; Dalsky GP; Martin JS; Eriksen EF
    J Bone Miner Res; 2005 Jul; 20(7):1244-53. PubMed ID: 15940379
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
    Biermasz NR; Hamdy NA; Janssen YJ; Roelfsema F
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body.
    Chevalier Y; Quek E; Borah B; Gross G; Stewart J; Lang T; Zysset P
    Bone; 2010 Jan; 46(1):41-8. PubMed ID: 19800436
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The effect of vitamin D receptor BsmI genotype on the response to osteoporosis treatment in postmenopausal women: a pilot study.
    Creatsa M; Pliatsika P; Kaparos G; Antoniou A; Armeni E; Tsakonas E; Panoulis C; Alexandrou A; Dimitraki E; Christodoulakos G; Lambrinoudaki I
    J Obstet Gynaecol Res; 2011 Oct; 37(10):1415-22. PubMed ID: 21651652
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
    Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S
    Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium homeostasis.
    Jacobs JW; de Nijs RN; Lems WF; Geusens PP; Laan RF; Huisman AM; Algra A; Buskens E; Hofbauer LC; Oostveen AC; Bruyn GA; Dijkmans BA; Bijlsma JW
    J Rheumatol; 2007 May; 34(5):1051-7. PubMed ID: 17407214
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy.
    Kaufman JM; Orwoll E; Goemaere S; San Martin J; Hossain A; Dalsky GP; Lindsay R; Mitlak BH
    Osteoporos Int; 2005 May; 16(5):510-6. PubMed ID: 15322742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.